Drugs / GSK626616
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00443170 | Nov 2006 → ? | anemia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK626616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00443170 ↗ |
| Action | Inhibit | “YAK3/DYRK3 Inhibitor” NCT00443170 ↗ |
| Route | Oral | “Oral GSK626616AC” NCT00443170 ↗ |